Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nicotinamide riboside malate
- Development stage
- Preclinical
- Lead developer
- Biosynth
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nicotinamide riboside malate (NRHM) is a small molecule dietary supplement and research compound that serves as a potent precursor to nicotinamide adenine dinucleotide (NAD+). It consists of nicotinamide riboside (NR), a vitamin B3 analog, ionically bonded with L-malic acid (malate). Developed by companies such as Thorne HealthTech and Biosynth Carbosynth, NRHM was designed to offer superior stability, solubility, and manufacturing parameters compared to the more common nicotinamide riboside chloride salt. Upon oral ingestion, NRHM is converted into NAD+, which subsequently activates sirtuins, specifically SIRT1 and SIRT3. These proteins are critical regulators of cellular metabolism, mitochondrial biogenesis, and DNA repair. NRHM is currently being investigated for its potential therapeutic applications in metabolic disorders, cardiovascular conditions, age-related pathologies, and neurodegenerative diseases such as Alzheimer's disease.
- Other names
- nicotinamide riboside hydrogen malateNRHM1-(beta-D-ribofuranosyl)nicotinamide malate
02
Targets
NAD (Nicotinamide adenine dinucleotide)SIRT3 (NAD-dependent protein deacetylase sirtuin-3)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
Beyond the preview
Go deeper on nicotinamide riboside malate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nicotinamide riboside malate.